Document is current

Article History

Received: 14 October 2025

Accepted: 15 December 2025

First Online: 23 December 2025

Change Date: 13 February 2026

Change Type: Update

Change Details: The original publication was amended to correct misaligned values in Table 1.

Declarations

:

: The study received approval from the ethics committee of the Ludwig-Maximilians-University Munich (Project No. 19–699). All patients provided their written informed consent before entering the study.

: Not applicable.

: The authors declare that they have had or are having the following economic or personal ties to the pharmaceutical industry, consulting firms, payers, or healthcare providers: AS is or was member of the following advisory boards: Novartis, Lilly, Sanofi, Allergan, TEVA, and speaker or member of speaker boards on behalf of Novartis, Lilly, Sanofi, Allergan, TEVA. He acted as consultant for Sanofi and TEVA, received grant support for research or education from Novartis and acted as an editorial board member for Lilly, Sanofi and Novartis. GB was or is member of the following advisory boards: Novartis, Lilly, TEVA, Grünenthal, STADA, Organon and speaker or member of following speakers boards: Novartis, Lilly, TEVA, Grünenthal; Consultant: Novartis, Lilly, TEVA, Grünenthal, STADA, Organon; he received grant support for research or education from TEVA. CG is or was member of the following advisory Boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Perfood, Merz, Dr. Reddy`s, Vectura Fertin Pharma, Organon and TEVA, and speaker or member of the following speaker boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Reckitt-Benckiser and TEVA. He served in the following editorial boards: Acta Neurologica Scandinavia, Frontiers in Neurology, and Medizinischer Sachverständiger. XH is an employee of TEVA GmbH. AH is or was member of the following advisory Boards: Abbvie, Hormosan Pharma, Lundbeck, Novartis Pharma and TEVA, and speaker or member of the following speaker boards: Abbvie, Lilly, Hormosan Pharma, Novartis Pharma, Lundbeck, and TEVA. TK is or was member of the following advisory Boards: Allergan, and speaker or member of the following speaker boards: Allergan, TEVA, Lilly, Hormosan. LN was member of the following advisory boards: TEVA, Lilly, Lundbeck, Novartis and Hormosan and speaker or member of the following speakers’ boards: Lilly, Lundbeck, TEVA, Novartis, Abbvie and Hormosan Pharma He received grant support for research from TEVA and Lilly. He served in the editorial boards of Journal of Headache and Pain and Frontiers in Neurology.